The impact of sleep duration on physical activity in daily life in patients with idiopathic pulmonary fibrosis

Silva, Humberto; Mantoani, Leandro C.; Aguiar, Wagner Florentin; Gonçalves, Aline Ferreira Lima; Silva, Thatielle G da; Zamboti, Camile Ludovico; Ribeiro, Marcelo Leite; Probst, Vanessa S.; Pitta, Fábio; Camillo, Carlos Augusto

doi:10.1080/09593985.2022.2160679

Cited by 4 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data coming from the project on IPF was the baseline assessment of a longitudinal cohort study aiming to investigate clinical endpoints and prognosis in interstitial lung diseases. Even though there were some longitudinal data involved in the projects, all the data analysed in the present study were collected at the baseline moment only [14][15][16][17]. None of the mentioned projects had any impact on subjects' PADL at the baseline time; therefore, the present results were not influenced by the fact that a secondary analysis of partial data collected in other projects was performed.…”

Section: Methodsmentioning

confidence: 98%

“…Participants were referred by medical doctors or invited by letters/advertisements to join each respective project. The list of specific inclusion and exclusion criteria for each study can be found elsewhere [14][15][16][17]. Subjects were consecutively assessed/included in each of these three previous projects, and included currently in the present analysis if they fulfilled the following criteria: they had to be diagnosed with COPD, asthma (adults) or IPF according to international criteria [7,8,18,19]; they should have been clinically stable for at least four weeks prior to their baseline assessment (i.e., no exacerbation of the disease); they could not have participated in pulmonary rehabilitation programmes in the previous year; they could not have more than one of the respiratory diseases concomitantly; they could not have any severe orthopaedic, neurological, cognitive and/or psychiatric impairment hindering mobility.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Physical Activity Patterns among Three Major Chronic Respiratory Diseases

Mantoani,

Furlanetto,

Camillo

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Although the level of physical activity in daily life (PADL) plays a vital role concerning the health of subjects with chronic lung diseases, it remains uncertain how PADL patterns compare among different conditions. This study’s objective was to compare the PADL levels of subjects with COPD, asthma and idiopathic pulmonary fibrosis (IPF); and to investigate PADL behaviour in different diseases’ severity. Stable subjects who had not undergone pulmonary rehabilitation in the previous year were included. Subjects were divided into two subgroups according to disease severity: mild/moderate and severe/very severe. The primary outcome was time spent in moderate-to-vigorous physical activities (MVPA) (Actigraph GT3x) measured during one week over 12 h/day; other assessments included pulmonary function, peripheral muscle strength and exercise capacity. Comparisons among subgroups were corrected for age, BMI and sex. The analysis involved 119 subjects (47 asthma, 48 COPD and 24 IPF). Subjects with asthma had higher PADL levels than those with COPD and IPF (MVPA 18(14–22) vs. 8(4–12) vs. 7(1–12) min/day, respectively; p ancova = 0.002). Subjects with severe/very severe IPF had the lowest PADL level among all subgroups. Adult subjects with asthma have higher PADL levels than those with COPD and IPF, whereas patients with severe and very severe IPF are the most physically inactive subjects.

show abstract

Section: Methodsmentioning

confidence: 98%

Section: Methodsmentioning

confidence: 99%

Comparison of Physical Activity Patterns among Three Major Chronic Respiratory Diseases

Mantoani,

Furlanetto,

Camillo

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

Autologous P63+ lung progenitor cell transplantation in idiopathic pulmonary fibrosis: a phase 1 clinical trial

Zhang,

Zhou,

Shao

et al. 2024

Preprint

View full text Add to dashboard Cite

In idiopathic pulmonary fibrosis (IPF) patients, alveolar epithelium architectures are persistently lost and lung gas transfer function would decline over time, which cannot be rescued by conventional anti-fibrotic therapy. P63+ airway basal progenitor cells are previously reported to have great potential to repair damaged lung epithelium. Here, we successfully cloned and expanded the autologous P63+ progenitor cells from IPF patients to manufacture the cell therapeutic product REGEND001, which were further characterized by cell morphology and single-cell transcriptomic analysis. Subsequently, an open-label, dose-escalation exploratory clinical trial was conducted (CTR20210349). The primary outcome was the incidence and severity of the cell therapy-related adverse events (AEs); secondary outcome included other safety and efficacy evaluation in each dose groups. We treated 12 patients with ascending doses of cells: 0.6x, 1x, 2x and 3.3x 106 cells/kg bodyweight. The data revealed that P63+ basal progenitor cell was safe and well tolerated at all doses, with no dose-limiting toxicity or cell therapy-related severe adverse events observed. Patients in the three higher dose groups showed statistically significant improvement of lung gas transfer function as well as exercise ability after REGEND001 therapy. Resolution of honeycomb lesion was also observed in patients of higher dose groups. Altogether these initial results indicated that REGEND001 has a high safety profile and meanwhile shows preliminary efficacy in IPF patients.

show abstract

Autologous P63+ lung progenitor cell transplantation in idiopathic pulmonary fibrosis: a phase 1 clinical trial

Zhang,

Zhou,

Shao

et al. 2024

Preprint

View full text Add to dashboard Cite

In idiopathic pulmonary fibrosis (IPF) patients, alveolar epithelium architectures are persistently lost and lung gas transfer function would decline over time, which cannot be rescued by conventional anti-fibrotic therapy. P63+ airway basal progenitor cells are previously reported to have great potential to repair damaged lung epithelium. Here, we successfully cloned and expanded the autologous P63+ progenitor cells from IPF patients to manufacture the cell therapeutic product REGEND001, which were further characterized by cell morphology and single-cell transcriptomic analysis. Subsequently, an open-label, dose-escalation exploratory clinical trial was conducted (CTR20210349). The primary outcome was the incidence and severity of the cell therapy-related adverse events (AEs); secondary outcome included other safety and efficacy evaluation in each dose groups. We treated 12 patients with ascending doses of cells: 0.6x, 1x, 2x and 3.3x 10 6 cells/kg bodyweight. The data revealed that P63+ basal progenitor cell was safe and well tolerated at all doses, with no dose-limiting toxicity or cell therapy-related severe adverse events observed. Patients in the three higher dose groups showed statistically significant improvement of lung gas transfer function as well as exercise ability after REGEND001 therapy. Resolution of honeycomb lesion was also observed in patients of higher dose groups. Altogether these initial results indicated that REGEND001 has a high safety profile and meanwhile shows preliminary efficacy in IPF patients.

show abstract

The impact of sleep duration on physical activity in daily life in patients with idiopathic pulmonary fibrosis

Cited by 4 publications

References 57 publications

Comparison of Physical Activity Patterns among Three Major Chronic Respiratory Diseases

Comparison of Physical Activity Patterns among Three Major Chronic Respiratory Diseases

Autologous P63+ lung progenitor cell transplantation in idiopathic pulmonary fibrosis: a phase 1 clinical trial

Autologous P63+ lung progenitor cell transplantation in idiopathic pulmonary fibrosis: a phase 1 clinical trial

Contact Info

Product

Resources

About